Subscribe

For The Earth Corp. (FTEG)

USD0.00 +0.00 (+0.00%)
US OTC Healthcare Drug Manufacturers - Specialty & Generic
Address 20 E Thomas Road 85012
Phoenix, AZ, US
CEO Nelson W. Grist
Website ftegco.com
IPO 1996-12-18
CIK 932265 ISIN US34512L2025

Explore sections of this company profile

Description

For The Earth Corporation, established in Phoenix, Arizona, in 1993, is a global manufacturer and distributor of consumable household and pet-related goods. Operating both domestically and internationally, the company, which was known as Medjet Inc. until its name change in January 2011, provides an extensive selection of cleaning products for homes. These include items such as laundry detergents, fabric softeners, dryer sheets, dishwashing detergents, and various general household cleansers, sold through retail chains under its proprietary brands and as private labels. Beyond its home care offerings, For The Earth also features a diverse array of pet supplies. Key products in this line include "Litter To Go," an inventive disposable cat litter box crafted from corrugated material and pre-filled with litter, and "What Odor?", a biodegradable and non-toxic spray designed to neutralize unpleasant smells. The pet division also encompasses treats, toys, decorative feeding dishes, and other solutions for managing pet odors and stains. The company caters to a wide customer base, including individual retail consumers, direct-to-consumer sales, and industrial clients such as hotels, nursing homes, restaurants, and professional sports organizations.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
USD0.00 +0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
45.5K
Beta
-83.44
Free Float %
0.0%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.00% +9,900.00% +9,900.00% +9,900.00% +0.00% +9,900.00% +0.00% +0.00% -83.33% +0.00% -100.00%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
0.00
Ratings Trend (MoM)
Rating 2024-11 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-48.18
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Operational MOAT
✗ Below peers
  • Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    Q3'22: -100.0% (vs Q3'21)
  • EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    Q3'22: +96.1% (vs Q3'21)
  • FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    -360.9%
  • EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    -98.2%
  • ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    Q3'22: +15.3% (vs Q3'21)
  • Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +664.7% Q3'22: +12.6% (vs Q3'21)
  • Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    -15.13× Q3'22: -2,894.79× (vs Q3'21)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
WACC components (optional)
Ke (Cost of Equity) = Rf + β (-83.44) × ERP
WACC = 25% × Ke + 75% × Kd (19.0%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
Current price: 0.00
Enterprise Value: Equity Value: Terminal Value: TV as % of EV:

Base values reflect the latest available data for this company and market conditions.

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-212.0K
OE per share TTM
0.00
Owner's Yield
-5.73%
Maintenance CapEx ratio
Maint CapEx / Avg PPE
13.2%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
Total invested
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-164.5K
Shares Outstanding
4.40B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)
Filing date Form type Filing
2002-03-19 PRE 14A
2002-01-09 PRE 14A
2000-04-27 DEF 14A
2000-04-27 DEF 14A
1999-06-18 DEF 14A
1999-06-18 DEF 14A

Recent SEC filings

Recent SEC filings
Filing date Form type Filing
2022-01-13 QUALIF
2022-01-12 CORRESP
2021-12-22 CORRESP
2021-12-22 1-A/A
2021-12-01 UPLOAD
2021-11-18 1-A/A
2021-11-10 UPLOAD
2021-10-29 1-A
2021-08-12 8-K
2019-08-13 QUALIF

Executive team

NameTitleCompensationGender
Kelli Grist Vice President of Operations female
Kelli McClarren Secretary and Treasurer female
Marcus DeWood Chief Medical Officer
Nelson Grist Chief Executive Officer, President & Director male
ESG Rating
B
DRUG MANUFACTURERS - SPECIALTY & GENERIC
2004
E (Environmental)
62.3 / 66.0
Company / Sector avg.
S (Social)
54.5 / 70.0
Company / Sector avg.
G (Governance)
65.4 / 66.6
Company / Sector avg.
ESG Total
60.7 / 67.5
Company / Sector avg.
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings reports

Stock splits